InvestorsHub Logo
Followers 38
Posts 6544
Boards Moderated 1
Alias Born 04/03/2017

Re: None

Friday, 01/21/2022 9:45:27 PM

Friday, January 21, 2022 9:45:27 PM

Post# of 8305
New management is top-notch and methodical. The more I learn the more I'm impressed.

Acquisition Pivots this Firm to Psychedelic Drug Development

The exploration of psychedelics for mental health treatment represents a growing opportunity and this firm is ceasing its current operations to focus on drug development with its new acquisition.

Blue Water Ventures International, Inc. (OTCPK: BWVI) is changing its objective following the acquisition of Psycheceutical, Inc., a biotechnology company dedicated to the development and commercialization of psychedelic medicines.

Though a merger, BWVI acquired Psycheceutical, Inc. which resulted in Psycheceutical becoming a wholly-owned subsidiary of BWVI, per the company’s press release. Following all necessary regulatory approvals, the company will proceed with a name and symbol change.

Psycheceutical brings a team with over 100 years' combined experience in development, regulatory approval processes and commercialization across the pharmaceutical industry.


My opinion is just my opinion and not a recommendation to buy or sell anything.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BWVI News